BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (April 2024)
35 slides from BeyondSpring's investor presentation, Apr 9, 2024
Slide 1: BeyondSpring Corporate Presentation April 2024
April 2024| NASDAQ: BYSI
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Investment Highlights
Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres
Slide 4: Pipeline
Pipeline Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name / Collaborator NSCLC Plinabulin + Docetaxel DUBLIN-3 (2nd/3rd line) Late stage Plinabulin + PROTECTIVE-1 CIN Prevention Pegfilgrastim & PROTECTIVE-2 SCLC Plinabulin + PD-1 + (2nd/3rd line) CTLA-4 NSCLC (2n
Slide 5: SEED Therapeutics: Target Protein Degradation (TPD 2.0) Company
SEED Therapeutics: Target Protein Degradation (TPD 2.0) Company TPD Targets 80% of Disease-Causing Proteins That are Currently Undruggable 5
Slide 6: Targeted Protein Degradation Addresses 80% of Disease-Causing Proteins
Targeted Protein Degradation (TPD) Addresses 80% of Disease- Causing Proteins That are were Undruggable TPD for Undruggable Proteins Druggable Proteins Sriram et al., Molecular Pharmacology, 2018 6
Slide 7: TPD Development History and Recent Renaissance
TPD Development History and Recent Renaissance SEED Co-founders played pivotal roles in the TPD Process advancement of TPD field • 1996: Dr. Michele Pagano (SEED co-founder) discovered cell cycle regulation by TPD, including E3 ligases; published in Science • 1999: Dr. Lan Huang (SEED co-founder and
Slide 8: World Class Leadership Team and Exceptional Insights in TPD Drug Development
World Class Leadership Team and Exceptional Insights in TPD Drug Development Lan Huang, PhD + * Avram Hershko MD, PhD+ Ning Zheng, PhD+ Michele Pagano, MD + (Chairman & CEO) “Godfather” of TPD; Howard Hughes Professor, University of Howard Hughes Professor, NYU E3 structural expert; Serial biotech 2
Slide 9: Exceeding Seed Financing Expectations
Exceeding Seed Financing Expectations SEED Internal Program Milestones Translation of SEED Platforms into Drug Development of SEED’s unique TPD platforms and filed Infrastructure and Organization Pipeline of 8 disclosed programs in patents Building various disease areas • Multi-dimensional platforms
Slide 10: SEED's Differentiation: Multi-dimensional Platforms for E3 Selection
SEED’s Differentiation: Multi-dimensional Platforms for E3 Selection Knowledge-based Direct Binding Validation LumID: Identify the right E3 in the Quasi Degron Approach “living cell” near protein of interest B B E3 B Target Neo Target Neo Target 1 Quasi Degron B Weakened Binding I L I L E3 C A A E3
Slide 11: Drug R&D Pipeline in Multiple Disease Areas
8 Drug R&D Pipeline in Multiple Disease Areas Target Molecular IND Indication Target Protein E3 Ligase ID Lead ID IND Filing Selection Glue HTS Candidate 2025 RBM39 FHD KRAS-G12D Oncology Target Beta FEN1 Target Alpha Neurodegeration Tau Immunology Target Gamma Antiviral HBx * SEED owns global IP on
Slide 12: Our RBM39 Degrader Class: Potentially Best-in-Class and First-to-Market
Our RBM39 Degrader Class: Potentially Best-in-Class and First-to-Market Program Summary • POI: RNA splicing factor RMB39; E3: DCAF15; MOA: RMB39 degrader MG • Target indications: Biomarker selected colon cancer, prostate cancer, neuroblastoma, and others • Development stage: IND candidate; YE2024 IN
Slide 13: TPD: a High Value and Novel Therapeutic Modality
TPD: a High Value and Novel Therapeutic Modality All top 20 global pharma have TPD programs internally and / or through collaboration Allosteric effect based Covalent binder • Not MG selective Target-Centric • Discovery stage TPD assets has been commanding $35 - $60 libraries • Lack of evidence for
Slide 14: Summary: First to Market and Best in Class
Summary: First to Market and Best in Class Scalable Business TPD has potential to target 80% of undruggable disease-causing Model proteins. > 600 E3 ligases to be used for multiple disease areas. Target-Centric Identify the right E3 for POI to increase the success rate in drug Differentiation discov
Slide 15: Plinabulin: First-in-class Late Stage Clinical Asset for Cancer Treatment
Plinabulin: First-in-class Late Stage Clinical Asset for Cancer Treatment 15
Slide 16: First-in-class Asset: Plinabulin
First-in-class Asset: Plinabulin • Positive Phase 3 study in 2L/3L NSCLC, successfully demonstrated significant Advanced Clinical OS benefit, doubling 2-year, 3-year OS rate – proving plinabulin’s clinical Stage Agent utility • Promising efficacy data in combination with PD-(L)1 and radiation, in IO
Slide 17: Plinabulin is a Differentiated First-in-Class Tubulin Binder
Plinabulin is a Differentiated First-in-Class Tubulin Binder with a Uniquely Favorable Safety Profile Plinabulin is a reversible tubulin binder and does not change tubulin dynamics Conventional tubulin binding agents (such as taxanes, vinca alkaloids, and colchicine) alter tubulin dynamics upon bind
Slide 18: Plinabulin: Induce Innate and Adaptive Immunity
Plinabulin: Induce Innate and Adaptive Immunity By depolymerizing microtubules, plinabulin releases, or activates, immune-defense protein GEF-H1. This leads to dendritic cell maturation (the most potent APC). In WT DC cells, plinabulin can induce DC maturation, but not in GEF-H1 deleted DC cells2 Pl
Slide 19: Plinabulin's Immunomodulation and Neutropenia-Mitigating Activities
Plinabulin’s Immunomodulation and Neutropenia-Mitigating Activities Position it as a Valuable Partner for Immuno-Chemotherapy Combination Regimens These aspects result in an optimal scenario of added efficacy with potentially reduced toxicity. Dendritic Cells M1-like Macrophages Improves Safety* Pli
Slide 20: Plinabulin improves overall survival and enhances safety in 2L/3L NSCLC (Dublin-3 Study)
Plinabulin improves overall survival and enhances safety in 2L/3L NSCLC (Dublin-3 Study) 20
Slide 21: The EGFR-wild Type 2L/3L NSCLC Have Been a Historically Difficult Space
The EGFR-wild Type 2L/3L NSCLC Have Been a Historically Difficult Space in Which to Develop Treatment options in Attempts to address treatment 2L/3L NSCLC are limited needs have been challenging Docetaxel-based therapies are the mainstay therapy in 2L/3L Since Nivolumab’s approval 8 years ago, NSCLC
Slide 22: Plinabulin Evaluated in Combination with Docetaxel in a Phase 3 Study
Plinabulin Has Been Evaluated in Combination with Docetaxel in a Phase 3 Study with advanced, Pre-treated NSCLC Patients Docetaxel + Plinabulin vs. Docetaxel + Placebo in Patients with EGFR Wild-Type NSCLC Study Plan Primary endpoint Secondary endpoints • Global, randomized, single-blinded (patients
Slide 23: Plinabulin + Docetaxel Met its Primary Endpoint (OS)
Plinabulin + Docetaxel Met its Primary Endpoint (OS) and Showed Significant Improvement in Long-term OS Rate Docetaxel + Docetaxel + placebo Plinabulin Survival Probability (%) OS HR=0.82 mOS benefit 1.1 M Log rank p=0.0399 Log-rank p=0.0399 Months Subjects at Risk Docetaxel (75mg/m2) + placebo 281
Slide 24: Plinabulin Slows Progression and Increased Tolerability of Docetaxel
Plinabulin Not Only Slows Progressive disease, but Also Increased the Tolerability of Docetaxel and Increased Duration of Treatment Use of plinabulin significantly …allowing more patients to remain on reduced Grade 4 neutropenia docetaxel for a longer duration Grade 4 neutropenia, All Cycles Day 8 %
Slide 25: Plinabulin Successfully Improved Efficacy of SOC in 2L/3L NSCLC
Plinabulin Successfully Improved Efficacy of SOC in 2L/3L NSCLC, Proving its Clinical Utility, Despite Historical Failures in this Space The addition of plinabulin as a single agent added to 2L/3L NSCLC standard-of- care led to improved overall survival and enhanced safety Efficacy Safety and tolera
Slide 26: Encouraging RT+PD-1+Plinabulin clinical data demonstrates partnering potential
Encouraging RT+PD-1+Plinabulin clinical data demonstrates Plinabulin’s partnering potential with IO agents RT: Radiation therapy 26
Slide 27: Plinabulin Enhances the Cancer Immunity Cycle with Radiation and Anti-PD1
Plinabulin Enhances the Cancer Immunity Cycle When Used with Radiation and Anti-PD1 ② Plinabulin 2 Improved antigen presentation ③ Checkpoint Inhibitors Stimulate maturation of dendritic cells to increase antigen presentation. 3 Anti-tumor T cell activation Optimize T cell response 1 ① Radiation/Che
Slide 28: Plinabulin Evaluated in Multiple Immunotherapy Combination Trials
Plinabulin is Being Evaluated in Multiple Immunotherapy Combination Trials in Collaboration with Major Pharmaceutical Companies Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Trial Name / Collaborator ES-SCLC Plinabulin + PD-1 + (1st line) Etoposide / Platinum Investigator Initiated T
Slide 29: RT+anti-PD1+Plinabulin Triple Combination POC in Animals
RT+anti-PD1+Plinabulin Triple Combination POC in Animals Provides Evidence of Plinabulin’s Immunomodulatory activity Tumor reduction is most robust DC activation is most dramatic in triple I/O combination in triple I/O combination Plinabulin+ RT+PD-1 increased DC maturation T cell doubles in triple
Slide 30: Clinical PoC in Efficacy: Plinabulin Triple Combo Produces Responses
Clinical PoC in Efficacy: Plinabulin Triple Combo Produces Clinically Meaningful Responses in the Non-Irradiated Tumor Across Multiple Cancers after IO-failure Plinabulin triple combination led to 70% DCR Systemic abscopal effect seen comparing baseline and C3D1 (3 PR, 4 SD) in 10 IO-failed patients
Slide 31: Clinical PoC in MOA: Early Immune Activation in Responding Patients
Clinical PoC in MOA: Plinabulin-Responding Patients Show Early Immune Activation Evidenced by DC Maturation and Proinflammatory Monocytes in the Peripheral Blood In different cancers, DC maturation and anti-tumor inflammatory macrophages were observed in plinabulin-responding patients Proinflammator
Slide 32: Plinabulin as Potential Add-on Therapy to Current I/O Regimens
Plinabulin as Potential Add-on Therapy to Current I/O Regimens to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand the - >$30B global annual sales addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development 2L/3L: PD-1/PD-L1 relapsed/refr
Slide 33: Plinabulin's Multiple MoAs, Proven Clinical Activity, and Strong Patent Protection
Plinabulin’s Multiple MoAs, Proven Clinical Activity, and Strong Global Patent Protection are Highly Favorable for Partnerships with Immunotherapy Agents…and Beyond Lead Asset Plinabulin Proven clinical efficacy and Enhances the Strong global patent displays dual IO MOAs safety Cancer-Immunity cycle
Slide 34: Investment Highlights
Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres
Slide 35: www.beyondspringpharma.com
www.beyondspringpharma.com 35